REG - EMV Capital PLC - PDS: up to $22mn Registered Direct Offering

EMV CapitalAnnouncement

27/02/2025 16:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250227:nRSa7704Ya&default-theme=true

RNS Number : 7704Y  EMV Capital PLC  27 February 2025

For immediate release

 

EMV Capital plc

 

("EMVC" or the "Company")

 

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced
At-the-Market Under Nasdaq Rules

 

$11 Million Upfront with up to an Additional $11 Million of Aggregate Gross
Proceeds Upon the Cash Exercise in Full of the Warrants

 

EMV Capital plc (AIM: EMVC), the deeptech and life sciences VC investment
group, reports that its portfolio company PDS Biotechnology Corporation
(Nasdaq: PDSB) - a late-stage immunotherapy company focused on transforming
how the immune system targets and kills cancers, and in which it holds a 2.8%
direct holding - has announced that it has entered into securities purchase
agreements with new and existing healthcare focused institutional investors as
well as participation from certain directors of PDSB, for the purchase and
sale of 7,330,121 shares of its common stock (or common stock equivalents in
lieu thereof) and warrants to purchase up to an aggregate of 7,330,121 shares
of common stock in a registered direct offering priced at-the-market under
Nasdaq rules (the "Offering") at a combined purchase price of $1.50 for the
institutional investors and $1.66 for certain directors of PDS.

 

The closing of the Offering is expected to occur on or about February 28,
2025, subject to the satisfaction of customary closing conditions. The gross
proceeds from the Offering are expected to be approximately $11 million.

 

A.G.P./Alliance Global Partners is acting as sole placement agent for the
Offering.

 

PDSB intends to use the net proceeds from the Offering for research and
development expenses and general corporate purposes.

 

A full version of PDS Biotech's announcement can be accessed here:

 

https://pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/132-2025-news/972-iotechnnouncesupto22illionegisteredirect20250227
(https://pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/132-2025-news/972-iotechnnouncesupto22illionegisteredirect20250227)

 

-Ends-

 

For more information, please contact:

 EMV Capital plc                                                              via Rosewood

 Ilian Iliev, CEO

 Panmure Liberum (UK) Limited (NOMAD and Broker)                              +44 (0)20 7886 2500

 Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Rosewood (Financial PR)                                                      +44 (0)20 7653 8702
 John West / Llew Angus / Lily Pearce

 

 

About EMV Capital plc (EMVC)

 

EMV Capital plc, formerly known as NetScientific plc, is a deep tech and life
sciences venture capital investment group with an international portfolio of
high-growth companies.

With a strategic focus on generating superior returns for investors from the
fast-growing sectors and technologies that will define our future; EMV Capital
invests in, manages and strengthens early stage IP-rich companies.

EMV Capital holds both direct equity stakes and carried interest in its
portfolio companies, creating an evergreen structure that supports extensive
growth and value creation. EMV Capital's investment thesis is realised through
these capital sources:

·     capital-efficient investments through Group balance sheet;

·     fund management of the Evergreen EIS and Martlet Capital Funds;

·     syndicated investments leveraging its network of third-party
investors.

EMV Capital's approach is characterised by its proactive management style,
aiming to advance portfolio companies to critical value inflection points by
actively engaging with them. Companies are supported through Board
representation and the use of its Value Creation Services practice.

Headquartered in London, with a Cambridge presence and strong international
links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

www.emvcapital.com (http://www.emvcapital.com/)

 

About PDS Biotechnology

 

PDS Biotechnology is a late-stage immunotherapy company focused on
transforming how the immune system targets and kills cancers. The Company
plans to initiate a pivotal clinical trial to advance its lead program in
advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech's
lead investigational targeted immunotherapy Versamune(®) HPV is being
developed in combination with a standard-of-care immune checkpoint inhibitor,
and also in a triple combination including PDS01ADC, an IL-12 fused antibody
drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.

 

www.pdsbiotech.com
(https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fpdsbiotech.us4.list-manage.com%2ftrack%2fclick%3fu%3d407bd594246e0ad6fd93882af%26id%3d4baca8d283%26e%3d5ec0d8129e&c=E,1,KvEMXzHVPivn_h59beCKD2b_rhhDVx-4ziC0t3oALRfo2FM7mgMIuHWmX-SXM6LC6pgLg6lH76m1GY6b8W8CK4bNjoUm1xU8aSqWH3PZSIKX_Q_9GLwXuml0a9c,&typo=1)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FUREAKAXAAXSEFA